Of possible interest

Recent blogs about the World Intellectual Property Organization (WIPO) meetings are available at http://keionline.org/wipo.

The US Secretary General High Level Panel on Access to Medicine. KEI submissions.

Request to NIH and Army to use government royalty free or march-in rights in the prostate cancer drug Xtandi.

Proposal for a WTO Agreement on the Supply of Public Goods.

Prices and patents on drugs, vaccines and diagnosis of hepatitis.

Innovation inducement prizes, possibly as an alternative to IPR monopolies to reward successful innovation.

Now is a good time to donate money to KEI

KEI Timelines, on a variety of topics.


Governments can ration access to cancer drugs, or break patent monopolies. Why is rationing so popular?:

Pictures from the WIPO SCCR negotiations on a treaty for persons who are blind or have other disabilities

These are pictures from the WIPO negotiations on a treaty for persons who are blind or have other disabilities.

Non paper distributed at SCCR 22 at 1pm on Friday, on disabilities

In a major breakthrough on the WIPO negotiations on copyright exceptions for persons with disabilities, at around 1pm today, a non-paper "resulting from informal discussions among Argentina, Brazil, Ecuador, the European Union and its Member States, Mexico, Paraguay and the United States of America" was distributed at the WIPO SCCR 22.

A copy of the document is available here:


SCCR22: Intervention of Unión Latinoamericana de Ciegos (Latin American Union of the Blind)

On 16 June 2011, Pablo Lecuona delivered the following intervention on behalf of Intervention of Unión Latinoamericana de Ciegos at SCCR 22.

Gracias señor presidente.

Lo felicito ante todo por su elección al frente de este comité. hablo en Nombre de la Unión latinoamericana de Ciegos que reúne a las organizaciones de ciegos de los 19 países de América latina.

Report from SCCR 22 discussions of WIPO treaty for persons who are blind or have other disabilities

Members of the WBU delegation at WIPO SCCR 22

June 16, 10 am: There are good news and less good news to report from Geneva. While overall, things have moved in positive directions, with the US and the EU engaged in very constructive negotiations with Brazil and other treaty sponsors, there are still many frustrations.

SCCR 22: Opening statement of the Asian Group

Asian Group’s Statement
22nd session of the Standing Committee on Copyright and Related Rights
(15-24 June 2011)

1. I have the honour to take the floor on behalf of the Asian Group.

SCCR22: Opening statement of the Development Agenda Group

Development Agenda Group’s Statement
22nd session of the Standing Committee on Copyright and Related Rights
(15-24 June 2011)

Mr. Chairman,

Opening statement of Uruguay at WIPO's 22nd Standing Committee on Copyright and Related Rights

Comité Permanente de Derechos de Autor y Conexos – SCCR 22 – OMPI - Ginebra
Intervención de la Delegación de Uruguay. Ginebra, 15 de junio de 2011.

Gracias Señor Presidente,

Señor Presidente, reciba de nuestra delegación nuestras mas sinceras felicitaciones por su designación como Presidente del Comité Permanente de Derechos de Autor y Conexos SCCR y cuente con nuestro apoyo para hacer una exitosa gestión al frente de este importante comité.

Señor Presidente:

Pharmaceutical global R&D was 7.9 percent of sales in 2010

Using industry assertions of R&D spending, pharmaceutical related R&D spending by the private sector was less than 8 percent of global sales in 2010.

These are the data:

2010 Global R&D by all private companies: - $67.4 billion
Source: Page 2 of the 2011 PhRMA industry profile

2010 Global sales - $856 billion

KEI Intervention at UN HLM on HIV: De-Linking R&D costs from drug prices and the sustainability of treatment

un_hlm_panel_3_IMG_2446.JPGThese are the notes from my intervention today at the UN's High Level Meeting on HIV/AIDS in New York. The persons making statements from the floor were asked to keep their comments to two minutes, so the actual intervention was somewhat shorter. Jamie

2011 High-Level Meeting on
the comprehensive review of the progress achieved in realizing
the Declaration of Commitment on HIV/AIDS and

WHO Executive Board Decision 129(8): WHO reform for a healthy future

On Wednesday, 25 May 2011, the 129th session of the World Health Organization's Executive Board approved Decision, EB129(8) on "WHO reform for a healthy future". Reproduced below is the text of the Decision which is yet to be published on the WHO website in all 6 UN languages.

EB129(8) WHO reform for a healthy future

The Executive Board,

Karl De Gucht writes Andris Piebalgs on topic of European Union IPR demands on India and other developing countries

KEI has received a copy of a May 16, 2011 letter from Karl De Gucht to Andris Piebalgs, which discusses (1) the EU-India FTA, and (2) Relations between IPR and development policies.

Senator Sanders introduces two medical innovation prize bills in U.S. Senate to de-link R&D costs from drug prices

Sanders_IMG_3442.jpgOn Thursday, May 26, 2011, Senator Bernie Sanders (I-VT) introduced two bills in the United States Senate that would de-link R&D costs from drug prices. The bill names and numbers are as follows:

  • The Medical Innovation Prize Fund Act: S. 1137
  • The Prize Fund for HIV/AIDS Act: S. 1138

KEI Technical Meeting to Discuss Innovation Inducement Prizes, June 3, 2011

There is a growing interest in the use of innovation inducement prizes to stimulate investments in medical research and development.

  • The Obama Administration and the European Commission are exploring the role of innovation inducement prizes.
  • On May 31, 2011, the European Parliament is holding one of several meetings on innovation inducement prizes for medical technologies.
Syndicate content